Key Points BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback. However, BioNTech's pipeline still includes over 25 oncology candidates in Phase 2 and Phase 3 trials. 10 stocks we like better than BioNTech Se › BMO (NYSE: BMO) Capital Markets has been quite bullish about BioNTech SE (NASDAQ: BNTX) this year. However, that's no longer the case. On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform" rating to a "market perform" rating. BMO also lowered its 12-month price target for BioNTech from $128 to $105. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.